Royal Bank of Canada’s Seres Therapeutics MCRB Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | $1K | Buy |
107
+98
| +1,089% | +$1.15K | ﹤0.01% | 6902 |
|
|
2025
Q4 | $0 | Sell |
9
-287
| -97% | -$5K | ﹤0.01% | 7427 |
|
|
2025
Q3 | $6K | Sell |
296
-6,658
| -96% | -$106K | ﹤0.01% | 6650 |
|
|
2025
Q2 | $77K | Buy |
6,954
+6,732
| +3,032% | +$59.2K | ﹤0.01% | 5739 |
|
|
2025
Q1 | $3K | Buy |
222
+124
| +127% | +$1.94K | ﹤0.01% | 6506 |
|
|
2024
Q4 | $2K | Buy |
98
+91
| +1,300% | +$1.48K | ﹤0.01% | 6717 |
|
|
2024
Q3 | $0 | Sell |
7
-228
| -97% | -$4.63K | ﹤0.01% | 7192 |
|
|
2024
Q2 | $3K | Buy |
235
+121
| +106% | +$2.02K | ﹤0.01% | 6661 |
|
|
2024
Q1 | $2K | Sell |
114
-1,433
| -93% | -$30.9K | ﹤0.01% | 6684 |
|
|
2023
Q4 | $43K | Buy |
1,547
+867
| +128% | +$22.8K | ﹤0.01% | 6062 |
|
|
2023
Q3 | $32K | Buy |
680
+309
| +83% | +$23.6K | ﹤0.01% | 6002 |
|
|
2023
Q2 | $35K | Buy |
371
+164
| +79% | +$17.8K | ﹤0.01% | 5944 |
|
|
2023
Q1 | $23K | Sell |
207
-383
| -65% | -$41.4K | ﹤0.01% | 5973 |
|
|
2022
Q4 | $66K | Buy |
590
+509
| +628% | +$68.2K | ﹤0.01% | 5733 |
|
|
2022
Q3 | $11K | Sell |
81
-868
| -91% | -$88.9K | ﹤0.01% | 6386 |
|
|
2022
Q2 | $65K | Sell |
949
-197
| -17% | -$17K | ﹤0.01% | 5595 |
|
|
2022
Q1 | $162K | Sell |
1,146
-536
| -32% | -$82.4K | ﹤0.01% | 5273 |
|
|
2021
Q4 | $280K | Buy |
1,682
+1,385
| +466% | +$220K | ﹤0.01% | 5006 |
|
|
2021
Q3 | $41K | Buy |
297
+59
| +25% | +$11.5K | ﹤0.01% | 6279 |
|
|
2021
Q2 | $114K | Buy |
238
+113
| +90% | +$47.7K | ﹤0.01% | 5519 |
|
|
2021
Q1 | $52K | Sell |
125
-212
| -63% | -$97.6K | ﹤0.01% | 5852 |
|
|
2020
Q4 | $165K | Sell |
337
-315
| -48% | -$184K | ﹤0.01% | 4991 |
|
|
2020
Q3 | $370K | Buy |
652
+5
| +0.8% | +$1.66K | ﹤0.01% | 4105 |
|
|
2020
Q2 | $62K | Buy |
647
+125
| +24% | +$11K | ﹤0.01% | 5127 |
|
|
2020
Q1 | $37K | Buy |
522
+362
| +226% | +$24.3K | ﹤0.01% | 5295 |
|
|
2019
Q4 | $11K | Buy |
160
+130
| +433% | +$9.64K | ﹤0.01% | 6104 |
|
|
2019
Q3 | $2K | Hold |
30
| – | – | ﹤0.01% | 6292 |
|
|
2019
Q2 | $2K | Hold |
30
| – | – | ﹤0.01% | 6581 |
|
|
2019
Q1 | $4K | Hold |
30
| – | – | ﹤0.01% | 6344 |
|
|
2018
Q4 | $3K | Sell |
30
-25
| -45% | -$3.5K | ﹤0.01% | 6341 |
|
|
2018
Q3 | $8K | Buy |
55
+13
| +31% | +$2.1K | ﹤0.01% | 6073 |
|
|
2018
Q2 | $7K | Buy |
42
+7
| +20% | +$1.14K | ﹤0.01% | 5932 |
|
|
2018
Q1 | $5K | Sell |
35
-5
| -13% | -$959 | ﹤0.01% | 5930 |
|
|
2017
Q4 | $8K | Sell |
40
-96
| -71% | -$19.7K | ﹤0.01% | 5939 |
|
|
2017
Q3 | $43K | Buy |
136
+90
| +196% | +$24.6K | ﹤0.01% | 5504 |
|
|
2017
Q2 | $10K | Sell |
46
-18
| -28% | -$3.7K | ﹤0.01% | 5802 |
|
|
2017
Q1 | $14K | Buy |
64
+31
| +94% | +$6.29K | ﹤0.01% | 5806 |
|
|
2016
Q4 | $7K | Buy |
33
+18
| +120% | +$3.93K | ﹤0.01% | 6205 |
|
|
2016
Q3 | $4K | Buy |
+15
| New | +$5.26K | ﹤0.01% | 6031 |
|
|
2016
Q1 | – | Sell |
-1
| Closed | -$1K | – | 6541 |
|
|
2015
Q4 | $1K | Sell |
1
-14
| -93% | -$9.2K | ﹤0.01% | 6480 |
|
|
2015
Q3 | $9K | Buy |
+15
| New | +$12.2K | ﹤0.01% | 5937 |
|
Other funds holding MCRB
FP
VCM
VFT
Royal Bank of Canada's MCRB Position: Q1 2026 in Review
Royal Bank of Canada increased its Seres Therapeutics (MCRB) stake by 1,089% in Q1 2026, buying an estimated $1.15K and bringing the position to 107 shares worth $1K. The position accounts for ﹤0.01% of the portfolio, ranked #6902.
Royal Bank of Canada first reported a position in MCRB in Q3 2015 and has held it in 41 quarters since. The position peaked at $370K in Q3 2020. 33 funds tracked by Wall St. Rank hold MCRB as of Q1 2026.
- Royal Bank of Canada held 107 shares of Seres Therapeutics worth $1K as of Q1 2026.
- Royal Bank of Canada bought 98 Seres Therapeutics shares in Q1 2026, an estimated $1.15K.
- Seres Therapeutics made up ﹤0.01% of Royal Bank of Canada's portfolio in Q1 2026, its #6902 holding.
- Royal Bank of Canada first reported a position in Seres Therapeutics in Q3 2015 and has held it in 41 quarters since.
- Royal Bank of Canada's Seres Therapeutics position peaked at $370K in Q3 2020.
- 33 funds tracked by Wall St. Rank held Seres Therapeutics as of Q1 2026.
Based on Royal Bank of Canada's 13F filing for Q1 2026, filed 15 May 2026.